This project aims to conduct a prospective, single-center, randomized, open-label, two-arm study to compare the clinical efficacy and safety of bronchial arterial chemoembolization with drug-eluting beads (DEB-BACE) combined with serplulimab versus conventional intravenous chemotherapy combined with Serplulimab as first-line treatment for SCLC patients. The objective is to provide evidence-based support for clinical practice.

Inclusion Criteria:

• Age more than 18 years old, regardless of gender;
• SCLC diagnosis based on histopathology according to the Primary Lung Cancer Diagnosis and Treatment Guidelines (2018 edition);
• TNM stage II-IV;
• ECOG PS score ≤2;
• Predicted survival time more than 3 months;
• Provision of signed informed consent.

Exclusion Criteria:

• Previous interventional therapies such as iodine seed implantation (within the past six months), ablation, BACE, or immunotherapy;
• Concurrent presence of other incurable malignant tumors;
• White blood cell count less than 3×10^9/L, neutrophil absolute count less than 1.5×10^9/L, neutrophil/lymphocyte ratio equal to or greater than 3, platelet count less than 50×10^9/L, hemoglobin concentration less than 90 g/L;
• Hepatic and renal insufficiency (creatinine level exceeding 176.8μmol/L); Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels more than twice the upper limit of normal;
• Uncorrectable coagulopathy or concurrent active hemoptysis;
• Complicated with active infection requiring antibiotic treatment;
• Uncontrolled hypertension, diabetes, or cardiovascular disease;
• Allergy to contrast agents;
• Women who are pregnant or lactating.

Statistical analysis plan, informed consent form, and clinical study report can be shared with other researchers.

Within six months after the trial is completed.

Shared data is not available for downloading, but can only be browsed. To download the data, you must contact the researchers.

Shared data does not provide any private information of the participants.